-
Dual-specific antibody TR009 / ABL001 targeting VEGF / DLL4 treats gastroesic tumors with encouraging preclinical results
Time of Update: 2021-01-14
in the Notch path, Delta-like liage 4 (DLL4) plays an important role in affecting tumor angiogenesic angiogenesy, which inhibits the formation of new blood vessels and promotes the maturation of new blood vessels.
-
Clin cancer res: The results of the first clinical trial of the anti-tumor necrotic necrotogenic sub-antibody MK-4166 for the treatment of advanced solid tumors
Time of Update: 2021-01-14
A: Tumor size changes in extended cohort patients; B:ICI initial treatment patients' response and duration in dose incremental cohorts (n-45), the combined treatment group had a period of objective remission (ORR 2.2%).
-
2020 Latest global cancer data: Breast cancer has overtaken lung cancer as the world's largest cancer, with more than 3 million cancer deaths in China each year
Time of Update: 2021-01-14
Recently, the World Health Organization's International Agency for Research on Cancer (IARC) released the latest global cancer burden data for 2020. estimated the latest morbidity, mortality and canc
-
Clin Cancer Res: Entinot United Pim Single Anti-Treatment ICII Refracidable NSCLC
Time of Update: 2021-01-14
this paper reports the results of treatment with Pym monoant anti-entinote in patients with anti-PD-(L)1 drug-resistant/refractic non-small cell lung cancer in ENCORE 601 trials.
ENCORE 601 trial extended the queue to include patients with NSCLC who had progressed in the course of treatment with immuno-checkpoint inhibitors in the past.
-
Gastric Cancer: The most appropriate follow-up time after different stages of gastric cancer cure!
Time of Update: 2021-01-14
Surgeons often face an important question about how to plan follow-up after surgery to treat stomach cancer.
, gastric cancer treatment surgery is usually followed up for 5 years.
findings may help surgeons develop postoperative follow-up plans for patients with stomach cancer.
-
Clin Cancer Res: Navu single anti-Ipi single anti-inflixi single anti/cytoju single anti-treatment melanoma
Time of Update: 2021-01-14
TICIMEL (NTC03293784) study is an open-label, two-arm Phase IB clinical trial that recruited 14 patients with advanced and/or metastatic melanoma (Phase IIIc/IV) to receive navuda (1 mg/kg) and Ipi monoanti (3 mg/kg) combined Invlixi monoanti (5 mg/kg, n=6) or cyto-bead monoanti (400/200 mg, n=8).
-
Lynparza is approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers
Time of Update: 2021-01-14
helps doctors determine treatment options for individual patients to significantly delay the progression of the disease." Lynparza (olaparib) is the first PARP inhibitor and the first targeted therapy to block DNA damage response (DDR) in cells/tumors with HRR defects such as BRCA1 and/or BRCA2 mutations.
-
Clin Cancer Res: The efficacy of Narvon anti-fir alcohol and reed anti-treatment for advanced stomach cancer is available in the future!
Time of Update: 2021-01-14
the research process and dose recruits patients with advanced stomach cancer who have difficulty treating first-line chemotherapy to be treated with navuda (3 mg/kg, day 1 and 15) in combination with yew alcohol (80 mg/m2, 1/8 and 15 days) and remoly monoantigen (8 mg/kg, day 1 and 15), with a course of treatment every 4 weeks.
-
JAMA Oncology: High-risk HPV detection is used in cervical cancer screening in China
Time of Update: 2021-01-14
high-risk human papillomavirus (hrHPV) test has been shown to be an effective method for cervical cancer screening.
Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-Label, Randomized Clinical Trial.
-
KraS inhibitor Adagrasib compared to Sotorasib's treatment of lung cancer
Time of Update: 2021-01-14
II, the effectiveness data Adgrasib in the NSCLC queue, assessed 51 patients (14 from I./I.b; 37 from Phase II, although from different studies, but given the same dose), 45% of patients had objective Responses (23/51 patients, 5 of whom had unproven partial reactions and were still receiving treatment), 70% (16/23) of respondents had a optimal response of more than 40% to the tumor, and the patient's disease control rate was 96% (49/51).
-
FDA awards Ilixadencel 'orphan drug' for treatment of hepatocellular carcinoma (HCC)
Time of Update: 2021-01-14
, a pharmaceutical company, recently announced that the U.S. Food and Drug Administration (FDA) has awarded Ilixadencel the "Orphan Drug Title" (ODD) for the treatment of hepatocellular carcinoma (HCC).
-
Lu Yuqin: Abdominal aortic aneurysm after the removal of the intestinal fistula to coincide with the treatment of large bleeding mouth
Time of Update: 2021-01-14
at a recent academic conference, Dr. Lu Yuqin, from Vascular Surgery at Zhejiang Provincial People's Hospital, explained in detail the treatment of intestinal fistula and mouth haemorrhage after abdominal aortic aneurysm removal with a specific case.
-
Lancet Oncol: CD40 astrogenic monoclonal antibody APX005M combined chemotherapy to treat metastatic pancreatic cancer
Time of Update: 2021-01-14
the study was designed to assess the safety of APX005M (sotigalimab) and Gissytabin combined nab-yew alcohol and or non-navutamol to treat patients with pancreatic cancer to determine the recommended phase 2 dose.
-
NEJM: Rare! Mother-to-child cancer spread due to vaginal delivery!
Time of Update: 2021-01-14
, the first author of the article, concludes: "These cases suggest that mother-to-child transmission of cervical cancer may occur during vaginal delivery; " but dr Shannon Neville Westin and Debbie Saslow, gynaecologists at the University of Texas Anderson Cancer Center, disagree, arguing that evidence in support of caesarean section is still to be unearthed.
-
Eur Radiol: Use MRI texture analysis to identify immune esophageal cancer in the liver and predict survival
Time of Update: 2021-01-14
study aims to predict immunosytotypes (IPs) and total lifetimes (OS) in patients with endoheid bile tube cell carcinoma (ICC) through preoperative magnetic resonance imaging (MRI) texture analysis.
-
Genes Dev: Gu Wei Lab's ultimate weapon in analyzing p53's anti-cancer function , Iron Death and mTOR
Time of Update: 2021-01-14
in more than two decades of research, Professor Gu Wei's lab has resulted in a number of important achievements in p53 function and regulation (the main conclusions are published in more than a dozen CNS journals and several CNS sub-issues).
-
Eur Radiol: Is there any metastasis of the lymph nodes in front of patients with non-small cell lung cancer?
Time of Update: 2021-01-14
Objective: The purpose of this study is to establish the best machine learning (ML) model using 18F-fluorodeoxycycline glucose (FDG) positive electron emission fault scanning/computer fault scanning (PET/CT) to evaluate the metastatic vertical lymph nodes (MedLNs) of non-small cell lung cancer and compare the diagnostic results with 1stdicated results of nuclear medicine physicians.
-
Lancet Oncol: Deep learning models that predict microsatellith instability with HE staining slices!
Time of Update: 2021-01-14
randomly selected a subset of WSIS (20 each for MSS and MSI) from an external data set to compare the model's predictions with 5 gastrointestinal pathologists.
, the deep learning model predicted that MSI outpernumbered experienced gastrointestinal pathologists based on WSIS dyed by H.
-
Cell: Heavy found that chromosomes are a gel that helps explain the spread of cancer
Time of Update: 2021-01-14
Dr. Hilmar Strickfaden, the lead author of a model paper explaining the physical properties of chromatin and chromatin chambers, said he believes the discovery of chromatin gel-like states will provide guiding principles for future research that will allow humans to better understand how the physical properties of chromatin shape the function of the nuclei to ensure the health of cells and bodies!
-
Lancet oncol: Prognosis for radiation therapy in patients with oligocranscater metastasis solid tumors using stereotactic ablation
Time of Update: 2021-01-14
this paper reports the results of a national study of patients with extracranial oligopolytic tumors treated with SABR, the largest data set ever learned.
the study, the use of SABR in patients with oligocranspheric metastatic cancer was associated with high total survival and low toxicity, complementing the available evidence.
